Patients with baseline Ki67 exceeding the median value (12%) had a significantly improved EFS per higher increase in TK1 activity (HRadj = 0.34, 95% CI 0.12-0.96), but not those with Ki67 < 12% (HRadj = 1.44, 95% CI 0.44-4.75), when adjusted for tumor size, nodal status and stratified for ER status. Here, MKI67 is linked to neoplasm.